Diabetes refers to a category of metabolic diseases characterized by high blood sugar levels. Diabetes is caused by inadequate secretion of insulin within the pancreas. Some of the common symptoms of diabetes are frequent urination, excessive thirst, increased appetite, weight loss, and tiredness. Type 1, type 2 diabetes, and gestational diabetes are three types of diabetes. Type 1 is a multifactorial chronic and autoimmune condition in which the body produces little or no insulin in the pancreas.
According to Market Research Future (MRFR), the global type-1 diabetes treatment market is expected to cross USD 9.6 billion, with a CAGR of 7.9%. from 2019 to 2025 (forecast period).
The body requires insulin hormone to get glucose from the bloodstream to the cells to generate energy. Most forms of diabetes can be categorized as type 1a – Autoimmune disease, where the breakdown of pancreatic beta cells is observed, low insulin production disrupts blood glucose homeostasis, and mild cases of type 1b – Idiopathic Diabetes Mellitus. This type of diabetes is rare and occurs during childhood or adolescence, but can also be seen in adults.
The global market for type 1 diabetes is expected to grow significantly over the forecast period due to the rising prevalence of type-1 diabetes due to environmental and genetic factors. Unhealthy eating habits, growing geriatric population, increasing obesity, and sedentary lifestyles are the main contributors to the growth of the global type 1 diabetes industry. Governmental initiatives to control diabetes and the economic impact of the disease on health systems in several countries are expected to propel the market growth.
Whereas, intense reimbursement policies, adverse side effects of the medication, and high diagnosis and treatment costs are constraining factors for the growth of the global type 1 diabetes treatment market.
The global type-1 diabetes treatment market has been segmented into product and end-user.
Based on the product, the global market for type-1 diabetes treatment has been segmented into rapid-acting insulin, short-acting insulin, medium-acting insulin, long-acting insulin, and others. Rapid-acting insulin is the largest and fastest-growing market in this segment. The segment has been further divided into Admelog, Humalog, Novolog, and others. Short-acting insulin is effective for 3–6 hours. Medium-acting insulin is effective for 12–18 hours. Long-acting insulin is used for chronic cases and is effective for upwards of 24 hours. The segment has been further divided into Lantus, Levemir, and others. The segment for others includes ultra-long-term action insulin and inhaled insulin.
Get Free Sample Copy of Report:https://www.marketresearchfuture.com/sample_request/8199
Based on end-user, the global market for type-1 diabetes treatment has been segmented into hospitals and clinics, specialty centers, and others. Hospitals and clinics segment is expected to be the largest and fastest-growing market during the forecast period. Specialty Centers segment is catering exclusively to patients who have diabetes; these centers are being opened across the globe. The segment for others includes treatment at home and old age homes.
Regionally, the global type-1 diabetes treatment market has been segmented into five major segments, including the Americas, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Americas to dominate the global market for type 1 diabetes treatment due to the growing incidence of diabetes in the region. The U.S. is developing as a power market with a large number of children under 14 years of age who have type 1 diabetes relative to other countries in the region.
The Asia Pacific is expected to record a significant growth rate over the forecast period due to an increase in the region’s aging population, with India emerging as a potential market leader over the forecast period.
Get Covid-19 Impact Analysis on the Market:https://www.marketresearchfuture.com/enquiry/8199
Some of the leading participants in the global type-1 diabetes treatment market are Astellas Pharma (Japan),Novartis (Switzerland), Merck (US), Novo Nordisk (Denmark), Sanofi (France), Boehringer Ingelheim GmbH (Germany), AstraZeneca (UK), Abbott Laboratories (US), Mannkind Corporation (US), Novartis (Switzerland), Braun Melsungen AG (Germany), Macrogenics, Inc. (US), Pfizer Inc. (US), DiaVacs, Inc. (US), Biodel, Inc. (US).
Market Research Future
Office No. 528, Amanora Chambers
Pune – 411028
Phone: +1 646 845 9312
Market Research Future (MRFR) is a world-renowned market research company that offers a wide range of services, complete with accurate and precise analysis about diverse markets, sub-markets and target consumers. Our approach is a combination of extensive information and multiple data sources that help provide an exhaustive comprehension about the latest major developments to the client, in addition to future events and what measures and decisions to take on the basis of the same.
Our fast emerging market research firm is armed with an adept research analysts’ team that focuses on gathering useful data and analytics in terms of economic and technological advances. Our proficient analysts conduct industrial visits in a bid to achieve reliable and accurate information from established market participants. One of our foremost objectives is to keep the client well-versed with all the lucrative opportunities as well as challenges surrounding various global markets. We offer step-by-step guidance to our clients, through consulting and strategic services, enabling them to arrive at a practical and effective decision.